Bank Of New York Mellon Corp Gritstone Bio, Inc. Transaction History

Bank Of New York Mellon Corp

$538 Trillion
Q3 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	BUY	$2.13 - $3.74 $104,440 - $183,383	49,033 New	49,033 $136 Million
Q4 2022 Feb 14, 2023	BUY	$2.17 - $3.92 $106,401 - $192,209	49,033 New	49,033 $169,000
Q3 2022 Nov 14, 2022	SELL	$2.46 - $4.75 $4,969 - $9,595	-2,020 Reduced 3.95%	49,165 $126,000
Q2 2022 Aug 15, 2022	SELL	$1.77 - $4.34 $192,344 - $471,623	-108,669 Reduced 67.98%	51,185 $124,000
Q1 2022 May 11, 2022	BUY	$4.03 - $12.19 $10,099 - $30,548	2,506 Added 1.59%	159,854 $658,000
Q4 2021 Feb 11, 2022	SELL	$8.76 - $13.71 $17,747 - $27,776	-2,026 Reduced 1.27%	157,348 $2.02 Million
Q3 2021 Nov 12, 2021	BUY	$6.41 - $13.54 $168,339 - $355,587	26,262 Added 19.73%	159,374 $1.72 Million
Q2 2021 Aug 11, 2021	BUY	$8.13 - $10.2 $163,754 - $205,448	20,142 Added 17.83%	133,112 $1.22 Million
Q1 2021 May 13, 2021	BUY	$4.07 - $27.11 $98,990 - $659,369	24,322 Added 27.44%	112,970 $1.07 Million
Q4 2020 Feb 09, 2021	SELL	$2.57 - $4.22 $8,534 - $14,014	-3,321 Reduced 3.61%	88,648 $349,000
Q3 2020 Nov 12, 2020	BUY	$2.63 - $8.09 $189 - $582	72 Added 0.08%	91,969 $243,000
Q2 2020 Aug 12, 2020	BUY	$5.69 - $8.17 $55,847 - $80,188	9,815 Added 11.96%	91,897 $610,000
Q1 2020 May 06, 2020	BUY	$5.47 - $11.3 $984 - $2,034	180 Added 0.22%	82,082 $477,000
Q4 2019 Feb 14, 2020	BUY	$7.07 - $11.61 $21,994 - $36,118	3,111 Added 3.95%	81,902 $734,000
Q3 2019 Nov 07, 2019	SELL	$8.45 - $12.28 $9,049 - $13,151	-1,071 Reduced 1.34%	78,791 $680,000
Q2 2019 Aug 12, 2019	BUY	$9.2 - $15.7 $532,900 - $909,406	57,924 Added 264.04%	79,862 $890,000
Q1 2019 May 14, 2019	BUY	$9.97 - $18.96 $218,721 - $415,944	21,938 New	21,938 $292,000

Others Institutions Holding GRTS

# of Institutions

Shares Held

35.4M

Call Options Held

395K

Put Options Held

132K

View Full List

About Gritstone bio, Inc.

Ticker GRTS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,006,896
Market Cap $2.19M
Description
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder ...

More about GRTS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

News

Stay updated on Bank Of New York Mellon Corp with notifications on news.

Account